15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 11 firms covering Beam Therapeutics Inc, 8 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. The target range is very wide, $21.00 to $80.00 (about 3.8x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $48.09 sits 92% above the current $25.09. The rating mix has stayed broadly stable, with Buy-side ratings easing from 9 to 8 over recent months. On the fundamentals, the Street sees revenue growth near -47% this year and 28% next, consensus EPS building from about $-1.17 next quarter toward $-4.73 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS11 ratings
Moderate Buy
Strong Buy00%
Buy873%
Hold327%
Sell00%
Strong Sell00%
Based on 11 analysts giving stock ratings to Beam Therapeutics Inc.
As of Jul, 8 of 11 firms rate BEAM a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
BEAM EPS & revenue forecast
EPS · NEXT QUARTER
$-1.17
Range $-1.28 – $-0.96 · 12 analysts · +7% YoY
Next period, 12 analysts expect Beam Therapeutics Inc to earn $-1.17 a share (range $-1.28 – $-0.96), versus $-1.10 a year earlier. Full-year consensus is $-4.43, growing to $-4.73 the year after.
REVENUE · NEXT QUARTER
$17.3M
Range $10.0M – $35.0M · 12 analysts · +78% YoY
Revenue is expected to reach $17.3M (range $10.0M – $35.0M), +78.0% year-over-year. Full-year consensus is $78.9M, rising to $96.1M next year.
Top analysts covering Beam Therapeutics Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on BEAM.
#1
David Nierengarten
Wedbush · Rank #115
Buy
$65.00+159.1% to target
Overall win rate
41%
+ Follow
#2
Greg Harrison
Scotiabank · Rank #177
Buy
$40.00+59.4% to target
Overall win rate
38%
+ Follow
#3
Patrick R. Trucchio
HC Wainwright & Co. · Rank #203
Buy
$80.00+218.9% to target
Overall win rate
35%
+ Follow
#4
Luca Issi
RBC Capital
Hold
$26.00+3.6% to target
Coverage
—
+ Follow
#5
Gena Wang
Barclays
Hold
$21.00-16.3% to target
Coverage
—
+ Follow
BEAM stock forecast FAQ
What is BEAM's average 12-month price target?+
The 11 analysts with a live target average $48.09 for Beam Therapeutics Inc over the next 12 months, ranging from a $80.00 high to a $21.00 low.
Is BEAM stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 11 analyst ratings, 8 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for BEAM?+
The Street-high target is $80.00 (HC Wainwright & Co.), and the Street-low is $21.00 (Barclays). The average of all 11 active targets is $48.09.
How many Wall Street analysts cover BEAM?+
11 analysts have an active rating on Beam Therapeutics Inc, and 11 firms carry a live 12-month price target.
Who is the most accurate analyst covering BEAM?+
Among analysts who currently cover BEAM, David Nierengarten of Wedbush has the strongest overall Quantellect track record (Rank #115). Their current call is Buy with a $65.00 target.
What is Beam Therapeutics Inc's projected EPS for next quarter?+
The consensus estimate is $-1.17 per share (range $-1.28 – $-0.96) across 12 analysts. Full-year EPS is projected at $-4.43, rising to $-4.73 the following year.
How much revenue is Beam Therapeutics Inc expected to report next quarter?+
Consensus revenue is $17.3M (range $10.0M – $35.0M). Full-year revenue is projected at $78.9M, growing to $96.1M next year.
Have analysts been upgrading or downgrading BEAM lately?+
As of Jul, 8 of 11 firms rate BEAM a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their BEAM calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
